Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to -$1.32.

  • Allogene Therapeutics' EPS (Weighted Average and Diluted) rose 40.62% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.98, marking a year-over-year increase of 37.18%. This contributed to the annual value of -$1.32 for FY2024, which is 36.84% up from last year.
  • Per Allogene Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.32 for FY2024, which was up 36.84% from -$2.09 recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$1.32 during FY2024, and its lowest value of -$2.63 during FY2020.
  • In the last 3 years, Allogene Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$2.09 in 2023 and averaged -$1.93.
  • As far as peak fluctuations go, Allogene Therapeutics' EPS (Weighted Average and Diluted) surged by 49.05% in 2021, and later plummeted by 77.61% in 2022.
  • Allogene Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.63 in 2020, then soared by 49.05% to -$1.34 in 2021, then crashed by 77.61% to -$2.38 in 2022, then increased by 12.18% to -$2.09 in 2023, then skyrocketed by 36.84% to -$1.32 in 2024.